Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Director | May 06, 2026 | May 08, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 14, 2021 | June 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,371 |
Reported balance
After 2026-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 8,371 · Balance 8,371 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 14, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 14,479 |
Reported balance
After 2021-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-14 · Grant · Acquired 14,479 · Balance 14,479 F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date July 31, 2025 · Filed August 05, 2025
Section 16 reporting ended · disclosed 2025-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,783 |
Ending reported balance
After 2025-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-07-31 · Exercise / conversion · Acquired 12,036 · Balance 13,216 F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. Row 2 · 2025-07-31 · Tax withholding · Disposed 3,433 · Balance 9,783 F2: The number of ordinary shares withheld to satisfy tax withholding obligations arising out of the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,886 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Grant · Acquired 16,414 · Balance 21,886 F3: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,036 |
Reported balance
After 2025-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-31 · Disposition to issuer · Disposed 9,850 · Balance 12,036 F4: The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5: The number of RSUs forfeited is based on a percentage. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-31 · Exercise / conversion · Disposed 12,036 · Balance 0 F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU.
F2: The number of ordinary shares withheld to satisfy tax withholding obligations arising out of the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
F3: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU.
F4: The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest.
F5: The number of RSUs forfeited is based on a percentage.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 8, 2026 21:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 8,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000095 · form4.xml · derivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,371 Underlying: Common Stock · 8,371 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,682 | $46.63 | $264,951.66 |
DisclosureSEC source: 0001682852-26-000070 · form4.xml · nonDerivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,066 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 16,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000070 · form4.xml · derivative · entry 3 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 16,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000070 · form4.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:16 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 504 | $27.60 | $13,910.40 |
DisclosureSEC source: 0001682852-25-000092 · form4.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,515 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-25-000057 · form4.xml · derivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on October 2, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on October 2, 2025. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-25-000057 · form4.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: The shares subject to this restricted stock unit award vested in full on October 2, 2025. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 12,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-073798 · tm2522414-15_4seq1.xml · derivative · entry 5 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. F1 · derivative.exercise_date: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. F1 · derivative.expiration_date: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 9,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-073798 · tm2522414-15_4seq1.xml · derivative · entry 4 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,036 Underlying: Ordinary Shares · 9,850 shares Expires not disclosed F4 · derivative.exercise_price: The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F4 · derivative.expiration_date: The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 16,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-073798 · tm2522414-15_4seq1.xml · derivative · entry 3 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,886 Underlying: Ordinary Shares · 16,414 shares Expires not disclosed F3 · derivative.exercise_price: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU. F3 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU. F3 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 3,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-073798 · tm2522414-15_4seq1.xml · nonDerivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,783 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out of the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 12,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-073798 · tm2522414-15_4seq1.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 312 | $28.00 | $8,736.00 |
DisclosureSEC source: 0001127602-25-017354 · form4.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 580 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 16,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012936 · form4.xml · derivative · entry 3 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,233 Underlying: Common Stock · 16,233 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 892 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012936 · form4.xml · derivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012936 · form4.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:06 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000379 · tm2432211-6_4seq1.xml · derivative · entry 4 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,472 Underlying: Ordinary Shares · 1,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:06 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000379 · tm2432211-6_4seq1.xml · derivative · entry 3 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,976 Underlying: Ordinary Shares · 1,231 shares Expires not disclosed F3 · derivative.exercise_price: The reporting person entered into an agreement with the issuer pursuant to which the reporting person forfeited the right to receive 1,231 RSUs that would otherwise have vested in exchange for a payment from the issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:06 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000379 · tm2432211-6_4seq1.xml · nonDerivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,180 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:06 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 1,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000379 · tm2432211-6_4seq1.xml · nonDerivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 12:52 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 892 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025227 · form4.xml · derivative · entry 4 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892 Underlying: Common Stock · 892 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F5 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 12:52 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 1,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025227 · form4.xml · derivative · entry 3 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,439 Underlying: Common Stock · 1,439 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on October 2, 2025. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on October 2, 2025. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 12:52 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 5,100 | $0.00 Strike: $63.16 | $0.00 |
DisclosureSEC source: 0001127602-24-025227 · form4.xml · derivative · entry 2 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires 2034-10-02 F2 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 12:52 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 8,093 | $0.00 Strike: $63.16 | $0.00 |
DisclosureSEC source: 0001127602-24-025227 · form4.xml · derivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,093 Underlying: Common Stock · 8,093 shares Expires 2034-10-02 F1 · derivative.exercise_date: This option will become fully vested and exercisable on October 2, 2025. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 21:13 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 8,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-025522 · tm245307-10_4seq1.xml · derivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,207 Underlying: Ordinary Shares · 8,207 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 12:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040809 · doc4.xml · derivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 13,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049375 · doc4.xml · derivative · entry 1 Hussain Abbas · CIK 0001821956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,050 Underlying: Ordinary Shares · 13,050 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on September 2, 2020 and vest on September 2, 2021. F2 · derivative.expiration_date: Restricted share units were granted on September 2, 2020 and vest on September 2, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.